WT1 expression correlates with angiogenesis in endometrial cancer tissue

Anticancer Research

Volumn 30, Issue 8, 2010, Pages 3187-3192

  Dohi, Satoshi ^a   Ohno, Satoshi ^a,b   Ohno, Yumiko ^a   Kyo, Satoru ^a   Soma, Gen Ichiro ^c,d   Sugiyama, Haruo ^e   Inoue, Masaki ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^c TOKUSHIMA BUNRI UNIVERSITY   (Japan)

^d TOKYO UNIVERSITY OF SCIENCE   (Japan)

^e OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiogenesis; Immunohistochemistry; Wilms' tumor gene; WT1

Indexed keywords

CD31 ANTIGEN; VASCULOTROPIN; WT1 PROTEIN; VASCULOTROPIN A;

ABDOMINAL HYSTERECTOMY; ADULT; AGED; ANGIOGENESIS; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CANCER TISSUE; CELL PROLIFERATION; ENDOMETRIUM CANCER; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADICAL HYSTERECTOMY; SALPINGOOOPHORECTOMY; ENDOMETRIUM TUMOR; FEMALE; METABOLISM; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); VASCULARIZATION;

ADULT; AGED; ANTIGENS, CD31; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WT1 PROTEINS;

EID: 77957338375     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, Haber DA, Rose EA, Kral A, Yeger H, Lewis WH, Jones C and Housman DE: Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 60: 509-520, 1990.
2. Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH and Bruns GA: Homozygous deletion in Wilms tumors of a zinc-finger gene identified by chromosome jumping. Nature 343: 774-778, 1990. (Pubitemid 20065258)
3. Rivera MN and Haber DA: Wilms' tumour: connecting tumorigenesis and organ development in the kidney. Nat Rev Cancer 5: 699-712, 2005.
4. Sugiyama H: Wilms' tumor gene WT1: its oncogenic function and clinical application. Int J Hematol 73: 177-187, 2001.
5. Oka Y, Tsuboi A, Kawakami M, Elisseeva OA, Nakajima H, Udaka K, Kawase I, Oji Y and Sugiyama H: Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancers. Curr Med Chem 13: 2345-2352, 2006.
6. Yang L, Han Y, Suarez Saiz F and Minden MD: A tumor suppressor and oncogene: the WT1 story. Leukemia 21: 868-876, 2007.
7. Nakatsuka S, Oji Y, Horiuchi T, Kanda T, Kitagawa M, Takeuchi T, Kawano K, Kuwae Y, Yamauchi A, Okamura M, Kitamura Y, Oka Y, Kawase I, Sugiyama H and Aozasa K: Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod Pathol 19: 804-814, 2006.
8. Ohno S, Dohi S, Ohno Y, Kyo S, Sugiyama H, Suzuki N and Inoue M: Immunohistochemical detection of WT1 protein in endometrial cancer. Anticancer Res 29: 1691-1695, 2009.
9. Wagner N, Michiels JF, Schedl A and Wagner KD: The Wilms' tumour suppressor WT1 is involved in endothelial cell proliferation and migration: expression in tumour vessels in vivo. Oncogene 27: 3662-3672, 2008. (Pubitemid 351912975)
10. Lee SB and Haber DA: Wilms tumor and the WT1 gene. Exp Cell Res 264: 74-99, 2001.
11. van Loo PF, Mahtab EA, Wisse LJ, Hou J, Grosveld F, Suske G, Philipsen S and Gittenberger-de Groot AC: Transcription factor Sp3 knockout mice display serious cardiac malformation. Mol Cell Biol 27: 8571-8582, 2007.
12. Semenza GL: Angiogenesis in ischemic and neoplastic disorder. Annu Rev Med 54: 17-28, 2003.
13. Cohen MM Jr.: Vascular update: morphogenesis, tumors, malformations, and molecular dimensions. Am J Med Genet A 140: 2013-2038, 2006.
14. Cash J, Korchnak A, Gorman J, Tandon Y and Fraizer G: VEGF transcription and mRNA stability are altered by WT1 not DDS(R384W) expression in LNCaP cells. Oncol Rep 17: 1413-1419, 2007.
15. Yamamoto S, Tsuda H, Kita T, Maekawa K, Fujii K, Kudoh K, Furuya K, Tamai S, Inazawa J and Matsubara O: Clinicopathological significance of WT1 expression in ovarian cancer: a possible accelerator of tumor progression in serous adenocarcinoma. Virchows Arch 451: 27-35, 2007.
16. Sera T, Hiasa Y, Mashiba T, Tokumoto Y, Hirooka M, Konishi I, Matsuura B, Michitaka K, Udaka K and Onji M: Wilms' tumour 1 gene expression is increased in hepatocellular carcinoma and associated with poor prognosis. Eur J Cancer 44: 600-608, 2008.
17. Hylander B, Repasky E, Shrikant P, Intengan M, Beck A, Driscoll D, Singhal P, Lele S and Odunsi K: Expression of Wilms tumor gene (WT1) in epithelial ovarian cancer. Gynecol Oncol 101: 12-17, 2006.
18. Miyoshi Y, Ando A, Egawa C, Taguchi T, Tamaki Y, Tamaki H, Sugiyama H and Noguchi S: High expression of Wilms' tumor suppressor gene predicts poor prognosis in breast cancer patients. Clin Cancer Res 8: 1167-1171, 2002. (Pubitemid 34517654)
19. Ozalp S, Yalcin OT, Acikalin M, Tanir HM, Oner U and Akkoyunlu A: Microvessel density (MVD) as a prognosticator in endometrial carcinoma. Eur J Gynaecol Oncol 24: 305-308, 2003. (Pubitemid 36644620)
20. Salvesen HB, Gulluoglu MG, Stefansson I and Akslen LA: Significance of CD 105 expression for tumour angiogenesis and prognosis in endometrial carcinomas. APMIS 111: 1011-1018, 2003.
21. Ueda M, Terai Y, Kumagai K, Ueki K, Okamoto Y and Ueki M: Correlation between tumor angiogenesis and expression of thymidine Phosphorylase, and patient outcome in uterine cervical carcinoma. Hum Pathol 30: 1389-1394, 1999.
22. Kamat AA, Merritt WM, Coffey D, Lin YG, Patel PR, Broaddus R, Nugent E, Han LY, Landen CN Jr, Spannuth WA, Lu C, Coleman RL, Gershenson DM and Sood AK: Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res 13: 7487-7495, 2007.
23. Jo'sko J, Mazurek M: Transcription factors having impact on vascular endothelial growth factor (VEGF) gene expression in angiogenesis. Med Sci Monit 10: RA89-RA98, 2004.
24. Hanson J, Gorman J, Reese J and Fraizer G: Regulation of vascular endothelial growth factor, VEGF, gene promoter by the tumor suppressor, WT1. Front Biosci 12: 2279-2290, 2007.
25. Hammes A, Guo JK, Lutsch G, Leheste JR, Landrock D, Ziegler U, Gubler MC and Schedl A: Two splice variants of the Wilms' tumor 1 gene have distinct functions during sex determination and nephron formation. Cell 106: 319-329, 2001.
26. Kreidberg JA, Sariola H, Loring JM, Maeda M, Pelletier J, Housman D and Jaenisch R: WT-1 is required for early kidney development. Cell 74: 679-691, 1993. (Pubitemid 23259748)
27. Armstrong JF, Pritchard-Jones K, Bickmore WA, Hastie ND and Bard JB: The expression of the Wilms' tumour gene, WT1, in the developing mammalian embryo. Mech Dev 40: 85-97, 1993.
28. Gao X, Chen X, Taglienti M, Rumballe B, Little MH and Kreidberg JA: Angioblast-mesenchyme induction of early kidney development is mediated by WT1 and VEGFA. Development 132: 5437-5449, 2005.
29. Karth J, Ferrer FA, Perlman E, Hanrahan C, Simons JW, Gearhart JP and Rodriguez R: Coexpression of hypoxia-inducible factor 1-alpha and vascular endothelial growth factor in Wilms' tumor. J Pediatr Surg 35: 1749-1753, 2000.
30. Baudry D, Faussillon M, Cabanis MO, Rigolet M, Zucker JM, Patte C, Sarnacki S, Boccon-Gibod L, Junien C and Jeanpierre C: Changes in WT1 splicing are associated with a specific gene expression profile in Wilms' tumour. Oncogene 21: 5566-5573, 2002.